-
Sage Therapeutics (SAGE) PT Lowered to $60 at RBC Capital
-
Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
-
Sage Therapeutics to Present at Upcoming May Investor Conferences
-
Sage Therapeutics (SAGE) PT Raised to $89 at RBC Capital as the Company Heads into a Tranformative Year
-
RBC Capital Downgrades Sage Therapeutics (SAGE) to Sector Perform
-
Sage Therapeutics (SAGE) PT Lowered to $83 at RBC Capital; Sees Sell-Off on Biogen Deal as 'Excessive'
-
Sage Therapeutics (SAGE) WATERFALL Study Expands 'Meaningfully' - RBC
-
Sage Therapeutics (SAGE) PT Raised to $75 at RBC Capital
-
Pre-Open Movers 03/18: (VXRT) (APRN) (BNTX) Higher; (CZR) (BA) (ERI) Lower (more...)
-
RBC Capital Upgrades Sage Therapeutics (SAGE) to Outperform
-
RBC Capital Downgrades Sage Therapeutics (SAGE) to Sector Perform
-
Buy Sage Therapeutics (SAGE) Ahead of Ph3 Mountain Data - RBC Capital
-
Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
-
Sage Therapeutics (SAGE) PT Lowered to $249 at RBC Capital
-
Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
Sage Therapeutics (SAGE) PT Raised to $261 at RBC Capital
-
Sage Therapeutics (SAGE) PT Raised to $259 at RBC Capital Following PPD Survey
-
SAGE Therapeutics (SAGE) Asia Partnership Should Not Affect Potential Takeover - RBC
-
RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
-
Sage Therapeutics (SAGE) PT Lowered to $261 at RBC Capital
-
Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC
-
Biogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBC
-
SAGE Therapeutics (SAGE) Prices 3.5M Shares at $164
-
UPDATE: Sage Therapeutics (SAGE) PT Raised to $280 at RBC Capital; Potential 'Game-Changing' Data and Takeover
-
Sage Therapeutics (SAGE) PT Raised to $145 at RBC Capital
-
Sage Therapeutics (SAGE) PT Raised to $120 at RBC Capital, Street High
-
RBC Capital Starts Sage Therapeutics (SAGE) at Outperform
-
Notable Analyst Rating Changes 08/12: (ANF) (ICUI) (DF) Upgraded; (AMCC) (WHX) (TCK) Downgraded

